Home > Rheumatology > EULAR 2020 > Rheumatoid Arthritis > Immune-related AEs due to checkpoint inhibitors require care coordination

Immune-related AEs due to checkpoint inhibitors require care coordination

Conference
EULAR 2020
Studies have shown that cancer treatment with checkpoint inhibitors can lead to rheumatic and musculoskeletal immune-related adverse events (irAEs), but clear guidance for rheumatologists to manage these events was lacking. An EULAR task force was set up to combine expert opinions on how to manage irAEs without jeopardising the response to the checkpoint inhibitor therapy [1]. The EULAR task force, consisting of 23 experts, developed 4 over-arching principles and 10 recommendations on the matter [1]. The 4 principles are: irAEs may occur during treatment with checkpoint inhibitors; shared decision-making between patients, oncologists, and rheumatologists is needed; rheumatologists should take an active role in engaging with oncologists when they are managing patients who have musculoskeletal signs and symptoms; and rheumatologists should assist in differential diagnosis and mitigate musculoskeletal symptoms to an acc...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on